

DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
CENTERS FOR DISEASE CONTROL

MINUTES OF MEETING

Immunization Practices Advisory Committee
May 18, 1988
Atlanta, Georgia

The Immunization Practices Advisory Committee (ACIP) met in Conference Room 207 at the Centers for Disease Control, Atlanta, Georgia, on May 18, 1988. Those in attendance are listed below:

COMMITTEE MEMBERS PRESENT

Dr. Samuel L. Katz, Chairman
Dr. James D. Cherry
Dr. Jeffrey P. Davis
Dr. David S. Fedson
Dr. W. Paul Glezen
Dr. Caroline Hall
Dr. F. Marc LaForce

Ex Officio Members

Dr. John R. LaMontagne (NIH)
Dr. Gerald Quinnan (FDA)

Liaison Representatives

Dr. J. Michael Dixon (NACI)
Dr. Edward A. Mortimer, Jr. (AMA)
Dr. Michael R. Peterson (DoD)
Dr. Stanley A. Plotkin (AAP)
Dr. William Schaffner II (ACP)
Dr. Ronald C. Van Buren (AAFP)

Executive Secretary

Dr. Jeffrey P. Koplan

Members Absent

Dr. Stanley Broadnax
Ms. Betty Bumpers
Dr. H. Denman Scott

HHS STAFF PRESENT

Office of the Surgeon General
Dr. Ernest T. Takafiji, US Army

CENTERS FOR DISEASE CONTROL

Office of the Director
Mr. Kevin Malone

HHS STAFF PRESENT (continued)

CENTERS FOR DISEASE CONTROL

Center for Infectious Diseases

Ms. Nancy Arden
Dr. Robert Breiman
Dr. John Campbell
Dr. Bruce Gellin
Dr. James M. Hughes
Dr. Mark Kane
Dr. Alan Kendal
Dr. Suzanne Gaventa
Mr. Stephen Redd
Dr. John Spika

Center for Prevention Services

Dr. Roger Bernier
Mr. Larry Dodd
Dr. Brad Hersh
Dr. Alan Hinman
Dr. Sonja Hutchins
Dr. Karen Kaplan
Dr. Lauri Markowitz
Dr. Walter Orenstein
Dr. Peter Patriarca
Dr. Stephen Preblud
Dr. Myron G. Schultz
Dr. Paul Stehr-Green
Dr. Walter W. Williams

Epidemiology Program Office

Dr. Robert Gunn

Agency for International Development

Dr. Kimi Fens-Ying C. Lin

National Vaccine Program Office

Dr. Alan Hinman
Ms. Sandra Tolpin
Dr. Yuth Nimit
Dr. Daniel Lahn

Others Present

Lt. Christine Beadle
Dr. Michael Bronowicz
Dr. Pinya Cohen
Dr. Corry Dekker
Dr. H. Bruce Dull
Dr. Adele Franks
Dr. Jill Hackell
Dr. Carolyn Hardegree
Dr. Garry Humphreys
Dr. Saul Krugman
Dr. Victor Jegede
Dr. Leslye D. Johnson
Dr. Cynsie Johnson
Mr. Charles S. Marwick
Dr. Frank McCarthy
Dr. Ellen McGuire
Dr. Wayne Morges
Dr. Nadia Nogueta
Ms. Lisa Orange
Dr. Frederick C. Robbins
Dr. Karlyn Shedlowski

The meeting was opened at 8:30 a.m. on May 18 by Dr. Samuel L. Katz, Chairperson. Dr. Elaine Esber was represented by Dr. Gerald Quinnan, FDA.

Dr. James O. Mason, Director of CDC, presented a certificate and letter of appreciation to Dr. David S. Fedson in appreciation of his assistance and advice as a member of the Committee from July 1, 1984 - June 30, 1988.

Pneumococcal Vaccine

Dr. Robert F. Breiman, Division of Bacterial Disease, (DBD), Center for Infectious Diseases, (CID), CDC, discussed a study of pneumococcal bacteremia for 1986-1987 from Charleston County, South Carolina, repeating a study performed there in 1974-1976. Pneumococcal bacteremia rates were 2.3 times higher than in the previous study. The difference appears to be due to increased blood culturing of patients. The overall case-fatality remained high at 18 percent. Ninety-three percent of patients aged 20-64 had underlying diseases which would have placed them in a category for which pneumococcal vaccine is recommended.

Dr. John Campbell, Division of Bacterial Disease (DBD), CID, CDC, discussed the "CDC Pneumococcal Vaccine Efficacy Study". The overall efficacy of the 14-valent polysaccharide vaccine against bacteremic pneumococcal disease was 60 percent. Efficacy was relatively high in persons with common indications for vaccination. The duration of protection afforded by pneumococcal vaccine is at least 5 years.

Dr. John Spika, Division of Bacterial Disease (DBD), CID, CDC, briefly discussed methodology of recently published pneumococcal vaccine efficacy studies. He also briefed the Committee on information related to revaccination issues.

Dr. Katz assigned a sub-committee consisting of Drs. Hall, LaForce, Fedson, and Spika to look at the current formulation and circulate suggested modifications before the next meeting.

Dr. David Fedson, reported on a meeting held in Copenhagen March 28-30, 1988. This meeting was sponsored by WHO to determine how the pneumococcal vaccine might be used in Europe. A report will be sent out as soon as it is ready.

Adult Immunization and Influenza

Ms. Suzanne Gaventa, DVD, CID, CDC, summarized results of influenza surveillance in the U.S. during the 1987-88 influenza season. A strain of influenza A(H3N2) which differed antigenically from strains circulating previously was the most frequently isolated type of the influenza virus this season. Influenza B, although much less frequently isolated than influenza A(H3N2), also differed antigenically from previously circulating strains of the influenza B virus. Both influenza A(H3N2) and influenza B were associated with outbreaks in nursing homes and other long-term care facilities this season. Influenza A (H1N1), similar to the most prevalent strain isolated during the 1986-87 influenza season, was also isolated this season, but was

not associated with any reported outbreaks. Deaths from pneumonia and influenza reported from 121 cities as a percentage of total deaths exceeded the epidemic threshold for 9 weeks, beginning with the reporting week ending February 13.

Dr. Alan Kendal and Ms. Nancy Arden, Division of Viral Diseases, (DVD), Center for Infectious Diseases, (CID), CDC, distributed draft Recommendations for Prevention and Control of Influenza updating the 1988-89 information on the vaccine and antiviral agent available for the control of influenza. Proposed changes in the Recommendation were discussed by the committee and any special comments requested to be returned to Dr. Kendal and Ms. Arden as soon as possible.

Hepatitis B - Update

Dr. Adele Franks, Division of Reproductive Health, Center for Health Promotion and Education, CDC, gave a slide presentation on transmission of Hepatitis B among Indochinese refugee children born in the USA. Transmission of Hepatitis B continues to occur in these children even when their mothers are not carriers of the HBV.

Dr. Mark Kane, Hepatitis Branch, Division of Viral Diseases, (DVD), CID, CDC, discussed the study and questioned whether current ACIP recommendations were adequate to prevent Hepatitis B virus transmission among Asian children in the USA. He proposed that the ACIP discuss various strategies for more extensive HB vaccination in these groups in future meetings. Dr. Myron Tong, University of South Carolina, or Dr. James Chin (WHO) were mentioned as possible consultants. Dr. Kane then passed out a final draft of the ACIP statement on Prevention of Perinatal Transmission of Hepatitis B Virus: Prenatal Screening of All Pregnant Women for Hepatitis B Surface Antigen and asked to be contacted if there were additional comments.

Poliomyelitis Vaccines

Dr. Alan Hinman, Center for Prevention Services, CDC, reviewed the report by the Institute of Medicine (IOM) "An Evaluation of Poliomyelitis Vaccine Policy Options" held January 21-22, 1988 in Washington, DC. Because the ACIP wanted an independent, multidisciplinary consideration of poliomyelitis vaccine policy for the United States, the PHS requested the IOM to re-evaluate the status of poliomyelitis and polio vaccination and to advise the ACIP about the pros and cons of various immunization policies. To this end, the IOM convened an international committee of experts from the public and private sectors. The most recent scientific information available to guide decision making was presented and analyzed.

Dr. Katz introduced Dr. Frederick C. Robbins, Chairman, Committee on Evaluation of Poliomyelitis Vaccine, who presented the IOM report on 1) the pros and cons of the vaccination policy options considered; 2) recommendations on vaccination policy; and 3) suggestions for research to provide a more secure basis for future policy changes. Dr. Robbins led the ACIP committee in a discussion on oral poliomyelitis vaccines (OPVs) and inactivated poliomyelitis vaccines (IPVs).

After discussion, Dr. Katz accepted the IOM report with gratitude and asked that the committee members go through the report, study the surveys, study on-going reports of wild polioviruses and enhanced potency vaccine and bring as much information as possible concerning polio vaccine to the October meeting. Dr. Katz suggested that an ACIP sub-committee be appointed to come up with some recommendation for the fall meeting.

Measles Vaccine - Update

Dr. Walter Orenstein, Division of Immunization (IM), Center for Prevention Services (CPS), CDC, gave introductory comments on information to be presented on measles vaccine. Dr. Lauri Markowitz, IM, CPS, CDC, presented an overview of current epidemiology of measles, preventable and nonpreventable. A draft recommendation, Measles Prevention - Supplementary ACIP Statement, was distributed to ACIP members for their review. Two new strategies were recommended: 1) Changes in preschool vaccination schedule in areas with recurrent measles transmission--a routine 2 dose vaccination schedule for preschoolers be implemented; and 2) Changes in outbreak control strategies for school-based outbreaks--that all students in affected schools and unaffected schools at risk, who received their most recent dose of measles vaccine before 1980 be revaccinated. Dr. Katz requested that comments be sent to Dr. Markowitz by June 15.

Other ACIP Business

Dr. Hinman gave a brief update on the National Vaccine Advisory Committee.

Dr. James Cherry reported on the Loveday trial in England in which Lord Justice Stuart-Smith rendered a very studied and knowledgeable decision that pertussis vaccine has not been proven to cause permanent brain damage in young children.

Currently, Japanese B Encephalitis vaccine is available only for U.S. Government employees on official business.

With the thanks of the Chairman, the meeting was adjourned at 4:55 p.m.

I hereby certify that, to the best of my knowledge, the foregoing summary of minutes is accurate and complete.


Samuel L. Katz, M.D., Chairman 24 June 1988
Date